IL22 and graft versus host disease: In general, the present platform enables the generation of large numbers of ROR t +, IL-22-producing ILC3 in a GMP-compatible process, which could be exploited for future cellular therapies of clinical conditions characterized by the loss of gut barrier integrity including acute bacterial infections, GvHD, or inflammatory bowel disease.